Association between Hyaluronic Acid Injections and Time-to-Total Knee Replacement Surgery

Roy Altman; Michael Fredericson; Samir K. Bhattacharyya; Brad Bisson; Thomas Abbott; Sashidhar Yadalam; Myoung Kim

doi:10.1055/s-0035-1568992

The Journal of Knee Surgery, Table of Contents

J Knee Surg 2016; 29(07): 564-570
DOI: 10.1055/s-0035-1568992

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Association between Hyaluronic Acid Injections and Time-to-Total Knee Replacement Surgery

Authors

Roy Altman

¹Department of Medicine, University of California at Los Angeles, Los Angeles, California
Michael Fredericson

²PM&R Sports Medicine, Stanford University, Pavilion A Redwood City, California
Samir K. Bhattacharyya

³DePuy Synthes Mitek Sports Medicine (a Johnson & Johnson Co.), Raynham, Massachusetts
Brad Bisson

³DePuy Synthes Mitek Sports Medicine (a Johnson & Johnson Co.), Raynham, Massachusetts
Thomas Abbott

⁴HCL Technologies, Philadelphia, Pennsylvania
Sashidhar Yadalam

⁵Epidemiology and Health Informatics, Johnson and Johnson Co., New Brunswick, New Jersey
Myoung Kim

⁵Epidemiology and Health Informatics, Johnson and Johnson Co., New Brunswick, New Jersey

Abstract

This study assessed the association between hyaluronic acid (HA) injections and time-to-total knee replacement (TKR) surgery for patients with knee osteoarthritis (OA). Patients 18 to 64 years of age who had TKR surgery between January 1, 2006 and December 31, 2011 were identified from the MarketScan Commercial claims database. All patients had 6 years or more of continuous enrollment prior to TKR surgery. There were two cohorts (1) patients with HA injections prior to TKR surgery and (2) patients who did not have HA injections prior to TKR surgery. Time-to-TKR was defined as the total days from the date of diagnosis of knee OA on the patient's first visit to an orthopedic surgeon to the date of TKR surgery. Results included 22,555 patients who had TKR surgery: 14,132 in the non-HA and 8,423 in the HA cohort. In this retrospective analysis of patients undergoing TKR, the median Time-to-TKR surgery was 326 days for the non-HA and 908 days for the HA cohort, a difference of 582 days. Those receiving HA injections had a median 1.6-year longer Time-to-TKR surgery versus those who did not receive HA injections. These results have both clinical and economic implications.

Keywords

hyaluronic acid - knee osteoarthritis - total knee replacement surgery - viscosupplementation

Full Text

References

References
1 Lawrence RC, Felson DT, Helmick CG , et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58 (1) 26-35
2 Centers for Disease Control and Prevention. A National Public Health Agenda for Osteoarthritis; 2010. Atlanta, GA. www.cdc.gov/arthritis/docs/OAagenda.pdf . Accessed May 5, 2015
3 Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991–94. J Rheumatol 2006; 33 (11) 2271-2279
4 Fibel KH, Hillstrom HJ, Halpern BC. State-of-the-Art management of knee osteoarthritis. World J Clin Cases 2015; 3 (2) 89-101
5 Kopec JA, Rahman MM, Berthelot JM , et al. Descriptive epidemiology of osteoarthritis in British Columbia, Canada. J Rheumatol 2007; 34 (2) 386-393
6 Oleske DM, Bonafede MM, Jick S, Ji M, Hall JA. Electronic health databases for epidemiological research on joint replacements: considerations when making cross-national comparisons. Ann Epidemiol 2014; 24 (9) 660-665
7 Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2015; 23 (4) 507-515
8 Arnold W, Fullerton DS, Holder S, May CS. Viscosupplementation: managed care issues for osteoarthritis of the knee. J Manag Care Pharm 2007; 13 (4, Suppl) S3-S19 , quiz S20–S22
9 Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective: a population-based review of the fourth most common cause of hospitalization in U.S. adults. Orthop Nurs 2012; 31 (2) 85-91
10 Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am 2012; 94 (3) 201-207
11 Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015; 162 (1) 46-54
12 Mazières B, Bard H, Ligier M, Bru I, d'Orsay GG, Le Pen C. Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine 2007; 74 (5) 453-460
13 Hatoum HT, Fierlinger AL, Lin SJ, Altman RD. Cost-effectiveness analysis of intra-articular injections of a high molecular weight bioengineered hyaluronic acid for the treatment of osteoarthritis knee pain. J Med Econ 2014; 17 (5) 326-337
14 Weinstein AM, Rome BN, Reichmann WM , et al. Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am 2013; 95 (5) 385-392
15 Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007; 13 (2) 113-121
16 Waddell DD, Joseph B. Delayed total knee replacement with hylan G-F 20. J Knee Surg 2014;
17 Altman RD, Lim S, Steen R, Dasa V. Intra-articular hyaluronic acid delays total knee replacement in patients with knee osteoarthritis: Evidence from a large U.S. health claims database. Osteoarthritis Cartilage 2015; 23 (Suppl. 02) 403-404
18 Whitman CS, Allen D, Comadoll JL, Thomason HC, Oweida SJ. A retrospective study of SUPARTZ and repeat treatment of osteoarthritis pain in the knee. J Manag Care Med 2010; 13: 43-47
19 Turajane T, Amphansap T, Labpiboonpong V, Maungsiri S. Total knee replacement following repeated cycles of intra-articular sodium hyaluronate (500–730 Kda) in failed conservative treatment of knee osteoarthritis: a 54-month follow-up. J Med Assoc Thai 2009; 92 (Suppl. 06) S63-S68
20 Mar J, Romero Jurado M, Arrospide A, Enrique Fidalgo A, Soler López B. [Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis]. Rev Esp Cir Ortop Traumatol 2013; 57 (1) 6-14
21 Turajane T, Labpiboonpong V, Maungsiri S. Cost analysis of intra-articular sodium hyaluronate treatment in knee osteoarthritis patients who failed conservative treatment. J Med Assoc Thai 2007; 90 (9) 1839-1844
22 Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. Rheum Dis Clin North Am 2007; 33 (1) 71-86
23 Losina E, Walensky RP, Kessler CL , et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med 2009; 169 (12) 1113-1121 , discussion 1121–1122
24 Wylde V, Dieppe P, Hewlett S, Learmonth ID. Total knee replacement: is it really an effective procedure for all?. Knee 2007; 14 (6) 417-423